MHRA develops early support for medicines innovation

MHRA develops early support for medicines innovation

The MHRA is developing earlier regulatory support for medicines manufacturers. AdvanceGxP will help developers assess compliance requirements for emerging technologies before making substantial production and investment decisions.


The UK’s medicines regulator is developing a service to help manufacturers address compliance requirements earlier when introducing innovative production technologies, including artificial intelligence, robotics, and personalised medicine.

The Medicines and Healthcare products Regulatory Agency (MHRA) has secured funding from the Office for Life Sciences to develop and test AdvanceGxP, an initiative providing practical regulatory support for novel medicines technologies.

Its initial focus will be on advanced manufacturing, where new production methods can create uncertainty about the application of established Good Practice requirements.

The proposed service will help developers examine those requirements before committing to critical decisions about facilities, production equipment, manufacturing processes, validation, and investment.

Science, Innovation and Investment Minister Chris McDonald announced the initiative during the DIA–MHRA Global Summit in London on 17 November.

AdvanceGxP remains in development. The MHRA is establishing its eligibility criteria, operating arrangements, and the types of support it will initially provide. It is not yet accepting applications for regulatory advice.

Integrating compliance into development —

Medicines manufacturers must demonstrate that their production systems operate within the applicable regulatory framework, including requirements concerning product quality, process controls, and the reliability of manufacturing activity.

These obligations become more complex when a business introduces production technologies for which there is limited regulatory precedent.

Advanced manufacturing systems may use robotics and automation to carry out activities previously performed by staff, or incorporate AI into the monitoring and control of production processes.

Other technologies involve medicines manufactured in small quantities for individual patients, including treatments produced at or near hospitals and clinics.

Such methods can challenge assumptions underlying conventional pharmaceutical facilities and production arrangements.

Developers may need to establish how established Good Practice principles apply to unfamiliar equipment, manufacturing locations, process controls, and responsibilities.

Uncertainty at an early stage can affect commercial decisions about facility design and capital expenditure. Requirements identified only after construction or equipment procurement may necessitate changes to systems that are expensive to modify.

AdvanceGxP is intended to provide an opportunity to discuss those questions before significant technical and financial decisions have been made.

The MHRA plans to offer practical, principles-based advice rather than prescribe one particular technical solution.

It also intends to connect the service with existing regulatory routes, allowing organisations to identify the formal procedures that remain necessary as their technologies progress.

Advice without advance approval —

The service will not provide inspection clearance or a guarantee that a product, production process, or manufacturing facility will obtain regulatory approval.

Formal inspection and authorisation decisions will remain independent, with developers continuing to meet the relevant requirements when seeking permission to manufacture or supply medicines.

This distinction separates early regulatory engagement from an advance commitment about the outcome of a later assessment.

The MHRA will initially test AdvanceGxP with a limited number of participants while it evaluates demand, specialist capacity, and the forms of support most useful to developers.

There will be no charge for access during the testing and pilot phases. Any subsequent charging arrangements will be developed using evidence from those phases and communicated before fees are introduced.

Other chargeable MHRA services will continue to operate under their existing arrangements.

Organisations developing novel medicines technologies, applications involving AI, or sustainability innovations in chemistry, manufacturing, and controls can register their interest in helping shape the service.

An expression of interest is not an application for regulatory advice and does not guarantee participation in a pilot.

The initiative forms part of the MHRA’s wider Strategy to 2030, which includes earlier engagement with developers and the modernisation of regulation for emerging technologies.

AdvanceGxP will begin with a limited development and testing programme, with its longer-term operating model to be determined as the regulator evaluates the support required by manufacturers.

—



  • How to mitigate the impact of the memory shortages

    How to mitigate the impact of the memory shortages

    Memory shortages are creating difficult decisions across business technology estates. Chetan Visrolia, business development manager at SHI, outlines practical ways to prioritise workloads, optimise infrastructure, and manage procurement risks.


  • UK and Australia deepen life sciences cooperation

    UK and Australia deepen life sciences cooperation

    Britain and Australia are deepening cooperation across life sciences industries. Joint commitments cover biotechnology, clinical research, regulatory coordination, commercial development, and specialist manufacturing technologies.


  • UK investigates Chinese robotic mower imports

    UK investigates Chinese robotic mower imports

    Britain has opened an investigation into Chinese robotic mower imports. The Trade Remedies Authority will assess allegations of dumping and injury to UK manufacturers before determining whether protective duties are justified.